E utile correggere il deficit immunologico del paziente neoplastico? E con quali modalità?

Translated title of the contribution: Is it useful to correct the immunological deficit in cancer patients? And with what modality?

C. Franceschi, M. Chiricolo, F. Licastro, M. Orlandi, G. Bartolini, V. Tomasi

Research output: Contribution to journalArticle

Abstract

A certain degree of immunodepression appears to be present in some neoplastic patients. Many factors such as age and nutritional and hormonal state (particularly thymic factors and locally-acting hormones like prostaglandins of E series) are involved in this phenomenon. The literature shows that all these factors are very important in neoplastic processes and might strikingly contribute also to the extent of immunodepression observed in neoplastic patients. Moreover, the HLA genotype seems to effect the efficiency of the antineoplastic treatments. The authors think that immunodepression in neoplastic patients might be improved by immunomodulators such as zinc ions, thymic hormones and, possibly, inhibitors of prostaglandins of E series.

Translated title of the contributionIs it useful to correct the immunological deficit in cancer patients? And with what modality?
Original languageItalian
Pages (from-to)45-59
Number of pages15
JournalLa Ricerca in Clinica e in Laboratorio
Volume15 Suppl 2
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Is it useful to correct the immunological deficit in cancer patients? And with what modality?'. Together they form a unique fingerprint.

  • Cite this

    Franceschi, C., Chiricolo, M., Licastro, F., Orlandi, M., Bartolini, G., & Tomasi, V. (1985). E utile correggere il deficit immunologico del paziente neoplastico? E con quali modalità? La Ricerca in Clinica e in Laboratorio, 15 Suppl 2, 45-59.